Union State Bank Cancer Center, Nyack Hospital, Nyack, NY
Michael E. Rader , Mark Danese , Ze Cong , Marc Halperin , Yi Qian , Carsten Dietrich Goessl , Karen Chung
Background: It has become more important to understand the incremental cost/benefit of new medicines as healthcare costs rise. Subcutaneous Dmab is superior to intravenous ZA for prevention of SREs in pts with CRPC and BM (Fizazi, 2011). In addition, a lower proportion of pts receiving Dmab progressed to moderate/severe pain than those receiving ZA (Brown, 2011). Dmab can be used in pts regardless of renal status or concomitant use of nephrotoxic drugs. These analyses assess the lifetime, real world cost-effectiveness of Dmab vs ZA in pts with CRPC and BM from a US managed care perspective. Methods: A lifetime Markov model was developed to estimate SREs, quality adjusted life-years (QALYs), and costs. The relative rate reduction in SREs for Dmab vs ZA was based on a large head-to-head phase 3 trial (N=1,901). The real world SRE rate in ZA pts was derived from a large commercial claims database analysis (Hatoum, 2008). SRE QALY decrements were estimated using the time trade-off method (Matza, 2011). SRE costs were estimated from a nationally representative commercial claims database (Barlev, 2010). Wholesale acquisition drug cost (Analysource, 2011), drug administration, and renal monitoring costs (National Fee Analyzer, 2011) were included. Compliance and mortality were assumed to be the same in both groups. Costs and QALYs were discounted at 3% annually. Results: With a median pt survival of 1.7 years, Dmab reduced the number of SREs and increased pts’ QALY vs ZA. The lifetime cost/pt on Dmab was $7,430 higher than ZA. Cost/QALY gained was $65,134, commonly considered good value based on oncologists’ implied threshold in the US (Nadler, 2006). Cost/SRE avoided was $9,212. Conclusions: Dmab is cost-effective in preventing SREs in pts with CRPC and BM compared with ZA in the US. The overall value of Dmab is based on superior efficacy and more efficient administration.
Dmab | ZA | Diff | |
---|---|---|---|
Lifetime cost*/Pt | $74,404 | $66,975 | $7,430 |
Lifetime QALY/Pt | 1.005 | 0.891 | 0.114 |
Lifetime # of SREs/Pt | 3.228 | 4.035 | -0.807 |
Cost per QALY gained | $65,134 | ||
Cost per SRE avoided | $9,212 | ||
*SRE, drug, drug administration, and renal monitoring costs.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2012 ASCO Annual Meeting
First Author: Michael E. Rader
2021 Genitourinary Cancers Symposium
First Author: Aaron Philip Mitchell
2022 ASCO Genitourinary Cancers Symposium
First Author: Aaron Philip Mitchell
2011 ASCO Annual Meeting
First Author: N. D. Shore